Moderna begins clinical trials of influenza vaccine using mRNA
Moderna Announces First Participant Dosed in Phase 1/2 Study of Its Quadrivalent Seasonal Flu mRNA Vaccine | Moderna, Inc.
https://investors.modernatx.com/news-releases/news-release-details/moderna-announces-first-participant-dosed-phase-12-study-its
mRNA vaccine technology moves to flu: Moderna says trial has begun | Ars Technica
https://arstechnica.com/science/2021/07/mrna-vaccine-technology-moves-to-flu-moderna-says-trial-has-begun/
There are four types of influenza vaccine 'mRNA-1010' that Moderna has started clinical trials: type A (H1N1 subtype), type A (H3N2 subtype), type B (Yamagata strain), and type B (Victoria strain). It is said to have a protective effect against influenza virus, and the safety, responsiveness, and immunogenicity will be evaluated in 180 healthy adults over the age of 18 in the Phase 1/2 study.
The above four viruses continue to mutate over time, and their prevalence varies from year to year. Influenza vaccine prescriptions change every year in anticipation of changes in the flu virus, but Moderna said, 'Current flu vaccines are prescribed 6-9 months before the flu virus epidemic.' It points out that the efficacy rate may decrease if the outbreak of influenza virus is not predicted.
In addition, Moderna pointed out that 'current influenza vaccine efficacy rates are 40% to 60%.' 'Currently mainstream influenza vaccine manufacturing methods can cause unintended changes in vaccine protein.' The 'mRNA-1010' under development claims the possibility of solving these problems.
In addition, Moderna CEO Stephen Bansel said, 'The advantage of mRNA vaccine is that by combining various antigens, we can develop vaccines that have a protective effect against multiple viruses such as influenza virus, new corona virus, and RS virus, and viruses. Our goal is to develop a vaccine that allows people to obtain immunity to multiple viruses with an annual inoculation by combining mRNAs. 'It is,' he said, and is eager to develop a vaccine that can prevent multiple respiratory infections with a single inoculation.
In addition to 'mRNA-1010', which was announced to start clinical trials, Moderna is also working on the development of two types of influenza vaccines, 'mRNA-1020 ' and ' mRNA-1030'. Furthermore, it is revealed that mRNA vaccines against viruses such as respiratory syncytial virus, human immunodeficiency virus (HIV) , nipah virus, and dicavirus are under development.
Moderna, which succeeded in developing a new corona vaccine, announced that it will develop an 'HIV vaccine' --GIGAZINE
In addition, research institutes other than Moderna are also developing vaccines that prevent malaria and cancer using mRNA vaccine technology, and research on mRNA vaccines is drawing a great deal of attention.
Three mRNA vaccines that are expected to appear in the future, such as 'cancer vaccine' --GIGAZINE
Related Posts:
in Science, Posted by log1o_hf